ASMB (Assembly Biosciences) Ending Cash Position: $31.12 Mil (As of Mar. 2026)


ASMB Assembly Biosciences Inc ASMB
31 GF Score
Price $27.73
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Ending Cash Position?

Assembly Biosciences ASMB +3.93% 31 Ending Cash Position is $31.12 Mil as of Mar. 2026. GuruFocus rates ASMB with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Assembly Biosciences's Ending Cash Position for the quarter that ended in Mar. 2026 was $31.12 Mil.

Assembly Biosciences's quarterly Ending Cash Position increased from Sep. 2025 ($22.53 Mil) to Dec. 2025 ($58.45 Mil) but then declined from Dec. 2025 ($58.45 Mil) to Mar. 2026 ($31.12 Mil).

Assembly Biosciences's annual Ending Cash Position increased from Dec. 2023 ($19.84 Mil) to Dec. 2024 ($38.34 Mil) and increased from Dec. 2024 ($38.34 Mil) to Dec. 2025 ($58.45 Mil).

Assembly Biosciences Ending Cash Position Related Terms

Assembly Biosciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Assembly Biosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences Ending Cash Position Chart

Assembly Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.63 52.42 19.84 38.34 58.45

Assembly Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.41 24.01 22.53 58.45 31.12
ASMB
31GF Score
Assembly Biosciences Inc ASMB
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Assembly Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=38.344+20.106
=58.45

Assembly Biosciences's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=58.45+-27.33
=31.12

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $31.12 Mil mean?
Assembly Biosciences (ASMB) has a Ending Cash Position of $31.12 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Assembly Biosciences and its competitors.
Is Assembly Biosciences' Ending Cash Position too high?
Assembly Biosciences' current Ending Cash Position is $31.12 Mil. Overall, Assembly Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Ending Cash Position compare to CTNM and PRTA?
Assembly Biosciences' Ending Cash Position of $31.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current Ending Cash Position is $31.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current Ending Cash Position of $31.12 Mil. The current Ending Cash Position is $31.12 Mil. Assembly Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current Ending Cash Position is $31.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Assembly Biosciences Business Description

Other Exchanges V7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score

Get the complete analysis for ASMB

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.73
Price